Clinical Trials Logo

Kidney Calculi clinical trials

View clinical trials related to Kidney Calculi.

Filter by:

NCT ID: NCT03318926 Completed - Renal Stone Clinical Trials

Increased Tea Consumption is Associated With a Decreased Risk of Renal Stone Disease in a Taiwanese Population

Start date: June 2001
Phase: N/A
Study type: Observational

The objective of the this study was to examine the amount and duration of tea consumption in relation to the risk of renal stone disease.

NCT ID: NCT03307096 Recruiting - Clinical trials for Surgery--Complications

Evaluation of Two Different Treatments for Lower Pore Renal Stone: Microperc Vs FURS

Start date: November 17, 2017
Phase: N/A
Study type: Interventional

This is a prospect, randomized control trial to evaluate merits between microperc and FURS for lower pole renal stone

NCT ID: NCT03305835 Recruiting - Clinical trials for Rare Kidney Stone Diseases

Monogenic Kidney Stone - Genetic Testing

Start date: September 11, 2017
Phase:
Study type: Observational

This study will attempt to identify the specific gene (coded in the DNA) and changes (mutations) within that gene that are the cause of monogenic kidney stone disease. This study will help researchers determine the characteristics of the stone disease associated with specific genes and mutations. This information may help develop more effective treatments for monogenic kidney stone diseases.

NCT ID: NCT03281928 Recruiting - Kidney Stone Clinical Trials

Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

This study intends to characterize the affect of sodium and potassium citrate in the diet on renal function.

NCT ID: NCT03257306 Recruiting - Kidney Stone Clinical Trials

Magnetic Ureteral Stent Symptoms - a Comparison to Standard Ureteral Stent as Perceived By the Patient (MAGUSS)

MAGUSS
Start date: November 9, 2018
Phase: N/A
Study type: Interventional

The specific aim of this study is to validate our hypothesis that the magnetic ureteral stents have the same amount of adverse effects as the more commonly used non-magnetic ureteral stents. If this hypothesis would be confirmed then the usage of magnetic ureteral stents would be justified for both reducing patient discomfort by way of fewer cystoscopies and possibly also decreasing the overall expenditures of treatment.

NCT ID: NCT03243682 Active, not recruiting - Urologic Diseases Clinical Trials

The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones

Start date: September 1, 2016
Phase: N/A
Study type: Interventional

compare the outcomes of SWL for renal and upper lumbar ureteric stones using the alternating bidirectional approach versus the standard approach.

NCT ID: NCT03229889 Enrolling by invitation - Nephrolithiasis Clinical Trials

Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment

Start date: June 7, 2017
Phase: Phase 4
Study type: Interventional

Extensive literature exists on the use of alpha-blocker medications for the removal of kidney stones. Alpha blockers relax certain muscles and help small blood vessels remain open. They work by keeping the hormone norepinephrine (noradrenaline) from tightening the muscles in the walls of smaller arteries and veins, which causes the vessels to remain open and relaxed. This improves blood flow and lowers blood pressure. There are studies that demonstrate alpha-blockers decrease ureteral pressure and help the ureter "relax." Recent studies have shown that phosphodiesterase inhibitors may also help with ureteral stone passing. A phosphodiesterase inhibitor is a drug that blocks an enzyme that inhibits relaxation of smooth muscle. This means that it can help smooth muscle, such as the muscle that lines the ureter, to relax. While ureteral relaxation is helpful in the passage of ureteral stones, our study seeks to use this finding by pretreating participants with an older generation alpha blocker or a phosphodiesterase inhibitor prior to passage of a ureteral access sheath in cases in which ureteroscopy is being used to approach a ureteral or renal stone. By relaxing the ureter, it is possible that a larger access sheath can be safely placed. This may allow for facilitating passage of the ureteroscope and extraction of stone fragments while precluding the development of potentially damaging intrarenal pressure from the flow of irrigant. The ureteral access sheath also protects the ureter from damage during the procedure. Placement of the largest access sheath possible is helpful in that larger stone fragments can be retrieved, the flow of irrigant is improved, and the surgical field is kept clear of blood or debris. To date, nobody has studied whether use of an uro-selective alpha blocker, alone, or in combination with a 5 phosphodiesterase inhibitor will result in passage of larger access sheaths. In this study participants will be randomized into 1 of 4 categories: Flomax (alpha-blocker), Cialis (5-phosphodiesterase inhibitor), a combination of the 2, or a placebo arm. In this study the placebo, or no active drug, is the current standard of care and will serve as a control from the other 3 groups.

NCT ID: NCT03206515 Recruiting - Renal Calculi Clinical Trials

The 18F Peel-way Sheath Versus the 18F Access Sheath With a Suction-evacuation Function MPCNL for the Management of 2-5cm Size Kidney Stones

Start date: January 2016
Phase: N/A
Study type: Interventional

Percutaneous nephrolithotomy (PNL) has been considered as the first-line choice for the management of >20mm kidney stones. Microchannel percutaneous nephrolithotomy (Mini PCNL) which takes nephrolithotomy channel size less than or equal to 18, was first used in the treatment of children with kidney stones in 1997, then gradually applied to adult, aims to achieve the similar stone clearance rate as the standard channels, at the same time, reduce the complications. At present, the use of percutaneous renal surgery in our country is more than 18F plastic peel-away sheath, with the access sheath with a suction-evacuation function was first used by Guohua Zeng and so on. But there is still a lack of high quality evidence of Evidence-based medical evidence to compare the two kinds of sheath for the safety and effectiveness. Therefore, this study provides a reliable theoretical basis for the choice of the sheath for the treatment of 2-5cm size Kidney, and ultimately benefit patients with 20mm.

NCT ID: NCT03193177 Completed - Chronic Disease Clinical Trials

A Retrospective and Prospective Cohort Study of the 21-day Fasting-like Diet in Patients With Metabolic and Autoimmune Diseases

Start date: June 20, 2017
Phase:
Study type: Observational

Effectiveness of fasting or fasting-mimicking diet has been proved an effective approach to treat metabolic and autoimmune diseases in mice. However, clinical trials performing prolonged fasting with more than 7 days have not been reported. Investigators conduct an open label, phase I/II clinical trial to evaluate the safety and effectiveness of the 21-day fasting-like diet in the treatment of metabolic and autoimmune diseases.

NCT ID: NCT03189264 Active, not recruiting - Renal Stone Clinical Trials

Percutaneous Nephrolithotomy for Treatment of Kidney Stones Greater Than 2 cm

Start date: May 10, 2017
Phase: N/A
Study type: Interventional

Percutaneous nephrolithotomy (PCNL) is a minimally invasive procedure considered as the treatment of choice for the management of large-scale and fully-formed kidney stones.This procedure has a 5% risk of complications including bleeding, the lesion of the collecting system, the risk of urinary infection and bacteremia. New surgical tools such as dilatation of the nephrostomy tract with mechanical dilatation contribute to the reduction of these risks, together with an improvement in the operative times and a lower rate of complications. At present there are multiple scales measuring the lithiasic morphology (Guy, the STONE nephrolitometry score system and the nomogram of the Office of Clinical Investigation of the Endourology Society - CROES) which allow to evaluate the degree of complexity of the stone, the possibility of residual stones and the risk of complications. These tools allow us to do a better analysis of the risk factors of the patient who will be taken to this type of endoscopic procedure in order to decrease morbidity and complication rates. Hypothesis: The use of pneumatic dilators during percutaneous nephrolithotomy reduces the rates of intraoperative and postoperative complications, which would have an impact on hospitalization times and surgical success for the management of renal stone.